동반진단(CDx) 시장 - 경쟁 구도 분석(2026년)

The companion diagnostics market is undergoing significant transformation driven by the paradigm shift toward precision oncology, the increasing complexity of biomarker-guided therapeutic development, and the growing integration of molecular diagnostics into routine clinical practice. The market's evolution is characterized by the recognition that companion diagnostics are essential for identifying patients based on genetic, genomic, proteomic, or molecular biomarkers that predict treatment response, thereby improving therapeutic efficacy and minimizing unnecessary exposure to targeted drugs. The convergence of advanced molecular technologies, including next-generation sequencing, polymerase chain reaction, and immunohistochemistry, is enabling more comprehensive and standardized biomarker assessment. Pharmaceutical companies are expanding biomarker-driven clinical trials, increasing demand for multiplex molecular assays that improve patient stratification and clinical trial efficiency. Regulatory agencies continue to approve companion diagnostics alongside corresponding oncology therapeutics through coordinated regulatory pathways, while strengthening evidence requirements for clinical performance and analytical validation. The market is witnessing significant investment in liquid biopsy technologies, AI-enabled interpretation platforms, and strategic pharmaceutical-diagnostic collaborations, positioning companion diagnostics as a critical enabler of precision medicine across global healthcare systems.

Market Dynamics

Market Drivers

• The expansion of precision oncology therapeutics represents the primary driver for the companion diagnostics market. Precision oncology remains the primary growth driver because most targeted therapies depend on biomarker identification before treatment initiation. Pharmaceutical companies are continuing to expand biomarker-selected clinical trials as genomic discoveries identify new actionable mutations across multiple cancer types. This progression increases demand for validated companion diagnostics capable of accurately identifying eligible patients throughout clinical development and commercial practice. The expanding pipeline of targeted therapies therefore strengthens long-term demand for advanced molecular testing platforms, resulting in sustained growth in companion diagnostic utilization. The increasing adoption of comprehensive genomic profiling is further accelerating market growth through improved diagnostic efficiency. Comprehensive genomic profiling enables simultaneous evaluation of numerous actionable biomarkers from a single patient specimen. Clinical laboratories are increasingly replacing sequential single-gene testing with multiplex NGS workflows because broader molecular characterization improves diagnostic efficiency while conserving limited tissue samples. This transition supports faster therapeutic decision-making and increases utilization of high-throughput sequencing technologies across oncology care pathways. The growth of liquid biopsy applications is expanding diagnostic capabilities through minimally invasive testing. Liquid biopsy expands diagnostic capabilities by enabling minimally invasive detection of circulating tumor DNA and other molecular biomarkers. Healthcare providers are increasingly adopting blood-based testing for treatment monitoring and resistance mutation detection because repeated tissue biopsies often present clinical limitations. Diagnostic developers are responding by improving analytical sensitivity and expanding biomarker coverage. Strategic pharmaceutical-diagnostic collaborations are fundamental to market expansion through integrated development. Companion diagnostics require coordinated development with targeted therapeutics, making strategic partnerships fundamental to market expansion.

Market Restraints

• Clinical validation requirements remain extensive, increasing development costs and extending regulatory approval timelines for companion diagnostics. The rigorous evidence requirements create significant time and cost burdens for developers. Reimbursement policies differ across healthcare systems, limiting consistent adoption of advanced molecular testing despite demonstrated clinical utility. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Limited access to specialized molecular laboratories restricts implementation of complex companion diagnostic technologies in several healthcare settings. The shortage of specialized laboratories and trained personnel limits the scalability of advanced diagnostics. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Market Opportunities

• The expansion beyond oncology represents a significant opportunity as precision medicine extends into immunology, neurology, infectious diseases, and rare genetic disorders. Drug developers are exploring biomarker-guided treatment strategies across these therapeutic areas, creating opportunities for diagnostic manufacturers to diversify assay portfolios while reducing dependence on oncology-focused revenues. The integration of artificial intelligence in molecular interpretation is improving variant classification and clinical reporting. AI improves interpretation of complex genomic datasets by supporting automated variant classification and clinical reporting. Diagnostic companies are integrating advanced bioinformatics platforms because increasing biomarker complexity requires scalable analytical capabilities. The growth of multi-biomarker companion diagnostics is enabling support for multiple therapeutic decisions through one comprehensive assay. Targeted therapies increasingly depend on multiple genomic alterations rather than single biomarkers. Diagnostic developers are expanding multiplex testing platforms that evaluate several predictive biomarkers simultaneously. Increasing global regulatory harmonization is enabling broader commercialization opportunities. Regulatory authorities are continuing to strengthen international alignment for in vitro diagnostic evaluation and precision medicine standards.

Technology and Product Insights

• The technology landscape is characterized by the growing importance of comprehensive genomic profiling, liquid biopsy, and integrated bioinformatics platforms. NGS platforms are replacing multiple single-gene assays because comprehensive genomic profiling improves laboratory workflow efficiency while supporting a growing number of actionable biomarkers. PCR remains important for focused mutation detection where rapid turnaround is prioritized. IHC continues supporting protein biomarker assessment for biomarkers including PD-L1 and HER2. ISH remains essential for gene amplification and rearrangement detection. Liquid biopsy is gaining clinical acceptance because minimally invasive sampling supports treatment monitoring, resistance mutation detection, and longitudinal disease assessment. The segment analysis reveals that oncology represents the largest therapeutic segment because targeted cancer therapies increasingly depend on validated biomarker identification before treatment initiation. Pharmaceutical developers are expanding biomarker-enriched clinical programs as genomic discoveries continue identifying actionable mutations across multiple tumor types. Breast cancer represents one of the largest applications because HER2, PIK3CA, ESR1, BRCA1/2, and other actionable biomarkers increasingly determine treatment eligibility. NSCLC requires comprehensive molecular profiling for EGFR, ALK, ROS1, BRAF, RET, MET, KRAS, HER2, and NTRK before first-line targeted therapy. Reference laboratories occupy a central position within the companion diagnostics ecosystem because they perform high-complexity molecular testing at scale. The integration of AI is becoming increasingly important because AI improves interpretation of complex genomic datasets by supporting automated variant classification and clinical reporting.

Competitive and Strategic Outlook

• The competitive landscape features established diagnostics and life science companies alongside specialized precision oncology, molecular, and liquid biopsy providers. Roche remains the global leader because it combines one of the industry's largest oncology pharmaceutical portfolios with an extensive in vitro diagnostics business, enabling simultaneous advancement of targeted therapeutics and companion diagnostic assays. Agilent Technologies has established a strong position through its pathology, genomics, and molecular diagnostics capabilities, with its Dako immunohistochemistry portfolio remaining widely adopted for biomarker testing. QIAGEN continues expanding its companion diagnostics business through expertise in molecular testing, sample preparation, PCR technologies, and NGS solutions, collaborating extensively with pharmaceutical manufacturers. Thermo Fisher Scientific occupies a significant position through its comprehensive precision medicine ecosystem encompassing sequencing instruments, PCR platforms, bioinformatics, clinical laboratory solutions, and regulatory expertise. Illumina remains a foundational technology provider because its sequencing platforms underpin comprehensive genomic profiling across research, clinical development, and commercial oncology testing. bioMerieux is strengthening its presence by leveraging its expertise in molecular diagnostics, syndromic testing, and clinical microbiology while expanding precision medicine capabilities. Companies are pursuing product portfolio expansion through innovation in NGS panels, liquid biopsy assays, and AI-enabled interpretation tools. Strategic collaborations between diagnostic manufacturers and pharmaceutical companies are increasing, driven by the need for companion diagnostic development alongside targeted therapies. Recent key developments include NeoGenomics introducing an FDA-approved PTEN IHC companion diagnostic to identify prostate cancer patients whose tumors demonstrate PTEN loss and may be eligible for TRUQAP. CellCarta and Sonic Healthcare announced a partnership to support CDx commercialization through a global lab network. Labcorp announced nationwide availability of Agilent's PD-L1 IHC 22C3 pharmDx, the FDA-approved companion diagnostic used to identify patients with platinum-resistant ovarian cancer who may be eligible for KEYTRUDA. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

• The companion diagnostics market is positioned for sustained growth driven by the convergence of precision oncology, technological innovation, and regulatory support. The transition from single-analyte testing toward integrated multi-biomarker platforms represents a fundamental shift in precision medicine. While challenges related to clinical validation, reimbursement variability, and infrastructure limitations persist, strategic investments in technology, partnerships, and global capabilities are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with companion diagnostics evolving into an essential component of precision healthcare, supporting therapeutic development, patient selection, and improved clinical outcomes across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global Companion Diagnostics (CDx) Competitive Landscape Analysis Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Companion Diagnostics Industry Overview
• 3.3 Evolution of the Companion Diagnostics Market
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Oncology Companion Diagnostics Landscape
• 3.8 Companion Diagnostics Beyond Oncology
• 3.9 Biomarker Landscape Analysis
• 3.10 Approved Companion Diagnostics by Therapeutic Area
• 3.11 Companion Diagnostic-Drug Co-development Landscape
• 3.12 Companion Diagnostic Adoption Across Clinical Practice

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies
• 6.2 Product Innovation
• 6.3 Clinical Trial Analysis
• 6.4 Companion Diagnostic Pipeline Analysis
• 6.5 AI Integration in Companion Diagnostics
• 6.6 Digital Pathology & Digital Health Integration

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
  • 7.2.1 Premarket Approval (PMA)
  • 7.2.2 510(k)
  • 7.2.3 De Novo Classification
  • 7.2.4 CE Mark under IVDR
  • 7.2.5 National Regulatory Approval
  • 7.2.6 Simultaneous Drug-CDx Co-approval
  • 7.2.7 Follow-on Companion Diagnostic Approval
  • 7.2.8 Bridging Studies
• 7.3 Compliance Requirements

8. Global Companion Diagnostics (CDx) Competitive Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Biomarker Type
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Testing Methodology
• 8.5 Analysis by Clinical Application
• 8.6 Analysis by Regulatory Status

9. Global Companion Diagnostics (CDx) Competitive Landscape Segment Analysis (2021-2035)

• 9.1 By Technology Platform
  • 9.1.1 Polymerase Chain Reaction (PCR)
  • 9.1.2 Next-Generation Sequencing (NGS)
  • 9.1.3 Immunohistochemistry (IHC)
  • 9.1.4 In Situ Hybridization (ISH)
  • 9.1.5 Others
• 9.2 By Biomarker Type
  • 9.2.1 Genomic Biomarkers
  • 9.2.2 Protein Biomarkers
  • 9.2.3 Gene Expression Biomarkers
  • 9.2.4 Others
• 9.3 By Sample Type
  • 9.3.1 Tissue
  • 9.3.2 Blood (Liquid Biopsy)
  • 9.3.3 Others
• 9.4 By Therapeutic Area
  • 9.4.1 Oncology Indication
    • 9.4.1.1 Breast Cancer
    • 9.4.1.2 Non-Small Cell Lung Cancer
    • 9.4.1.3 Colorectal Cancer
    • 9.4.1.4 Melanoma
    • 9.4.1.5 Ovarian Cancer
    • 9.4.1.6 Hematological Malignancies
    • 9.4.1.7 Other
  • 9.4.2 Non-Oncology Indications
• 9.5 By End User
  • 9.5.1 Hospitals
  • 9.5.2 Reference Laboratories
  • 9.5.3 Academic & Research Institutes
  • 9.5.4 Others

10. Global Companion Diagnostics (CDx) Competitive Landscape Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global Companion Diagnostics (CDx) Competitive Landscape Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 South Korea
• 11.11 Australia
• 11.12 India
• 11.13 Brazil

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 Agilent Technologies, Inc.
• 13.3 QIAGEN N.V.
• 13.4 Thermo Fisher Scientific Inc.
• 13.5 Illumina, Inc.
• 13.6 BioMerieux
• 13.7 Exact Sciences
• 13.8 Guardant Health, Inc.
• 13.9 Foundation Medicine, Inc.
• 13.10 Abbott Laboratories

14. Global Companion Diagnostics (CDx) Competitive Landscape Commercial Forecast Analysis

• 14.1 Commercial Forecast by Companion Diagnostic Technology Platform
• 14.2 Commercial Forecast by Biomarker Category
• 14.3 Commercial Forecast by Therapeutic Area
• 14.4 Commercial Forecast by Sample Type
• 14.5 Commercial Forecast by End User

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends